Article Text

Download PDFPDF
Letter
Glial fibrillary acidic protein IgG related myelitis: characterisation and comparison with aquaporin-4-IgG myelitis
  1. Elia Sechi1,
  2. P Pearse Morris2,
  3. Andrew McKeon1,3,
  4. Sean J Pittock1,3,
  5. Shannon R Hinson3,
  6. Brian G Weinshenker1,
  7. Allen J Aksamit1,
  8. Karl N Krecke2,
  9. Timothy J Kaufmann2,
  10. Evan A Jolliffe1,
  11. Nicholas L Zalewski1,
  12. Anastasia Zekeridou1,
  13. Dean M Wingerchuk4,
  14. Jiraporn Jitprapaikulsan1,3,
  15. Eoin P Flanagan1,3
  1. 1 Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA
  2. 2 Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
  3. 3 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
  4. 4 Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
  1. Correspondence to Dr Eoin P Flanagan, Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA; flanagan.eoin{at}mayo.edu

Statistics from Altmetric.com

Introduction

IgG directed against the α-isoform of glial fibrillary acidic protein (GFAP-IgG) predicts a distinct corticosteroid-responsive meningoencephalomyelitis termed autoimmune GFAP astrocytopathy, when detected on cerebrospinal fluid (CSF).1 Optic disc oedema and tremor are common accompaniments. The MRI hallmark is a striking linear perivascular enhancement radially oriented around the ventricles (radial enhancement), while the myelitis component is generally associated with a longitudinally extensive T2 lesion on spinal cord MRI, similar to that typically encountered in aquaporin-4-IgG (AQP4-IgG) related myelitis.1–3 We compared the clinical, laboratory and MRI features of GFAP-IgG and AQP4-IgG related myelitis.

Materials and methods

Patient ascertainment

We retrospectively identified GFAP-IgG seropositive patients seen at the Mayo Clinic ( 1 January 2000 to 31 December 2017). Inclusion criteria were as follows: (1) serum/CSF demonstrating GFAP pattern by indirect immunofluorescence with GFAPα specificity confirmed by cell-based assay, as previously described;1 (2) first myelitis episode; (3) serum sample negative for myelin oligodendrocyte glycoprotein-IgG (MOG-IgG) and AQP4-IgG using previously described methodology4 5; (4) adequate clinical data available. Nine patients with GFAP-IgG myelitis were included in a prior report.1 Two patients with dual positivity in serum for AQP4-IgG and GFAP-IgG were excluded. Medical records were reviewed and compared with 41 patients from a previously identified cohort of AQP4-IgG seropositive patients at the first episode of clinical myelitis who tested negative for GFAP-IgG (41 tested) and MOG-IgG (13 tested).5 Improvement was defined as subjective improvement reported by the patient with objective improvement confirmed by the physician.

Neuroimaging

All available MRI sequences obtained within 4 months of myelitis onset were reviewed by one neurology investigator (ES/EPF) and one neuroradiologist (TJK/KNK/PPM) as described previously.5 Consensus was achieved in situations of disagreement.

Statistical analysis

Wilcoxon rank-sum test or χ2/Fisher’s exact test was used as appropriate for comparison (JMP 8.0 software).

Results

Fifty-four patients with myelitis were included: GFAP-IgG positive, …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.